Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.41 |
| ▸ | GABRR2 | P28476 | 2/20 | 0.41 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 5/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2977139 | 1.00 | BLM (0.41) | BLMTSHRGABRR1GABRR2GABRR3 | |
| Hydrochloric Acid SCHEMBL14636142 | 0.98 | BLM (0.39) | BLMTSHRGABRR1GABRR2GABRR3 | |
| Hydrochloric Acid SCHEMBL14636144 | 0.98 | BLM (0.39) | BLMTSHRGABRR1GABRR2GABRR3 | |
| SCHEMBL2972245 | 0.98 | CYP1A2 (0.41) | BLMTSHRGABRR1GABRR2GABRR3 | |
| SCHEMBL24306 | 0.98 | CYP1A2 (0.41) | BLMTSHRGABRR1GABRR2GABRR3 | |
| SCHEMBL24305 | 0.98 | CYP1A2 (0.41) | BLMTSHRGABRR1GABRR2GABRR3 | |
| SCHEMBL2972244 | 0.98 | CYP1A2 (0.41) | BLMTSHRGABRR1GABRR2GABRR3 | |
| Hydrochloric Acid SCHEMBL6624057 | 0.96 | ELANE (0.40) | BLMTSHRGABRR1GABRR2GABRR3 | |
| Hydrochloric Acid SCHEMBL6624060 | 0.96 | ELANE (0.40) | BLMTSHRGABRR1GABRR2GABRR3 | |
| SCHEMBL16901712 | 0.95 | BLM (0.41) | BLMTSHRGABRR1GABRR2GABRR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772243-B2 | 4-phenylamino-quinazolin-6-yl-amides | WARNER-LAMBERT COMPANY LLC (US) | 2010-08-10 | — | — | US | claimed |
| JP-4205757-B2 | — | — | 2009-01-07 | — | — | JP | claimed |
| JP-2007536368-A | — | — | 2007-12-13 | — | — | JP | claimed |
| EP-1746999-A1 | 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES | Warner-Lambert Company LLC (US) | 2007-01-31 | — | — | EP | claimed |
| WO-2005107758-A1 | 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES | WARNER-LAMBERT COMPANY LLC (US) | 2005-11-17 | — | — | WO | claimed |
| US-20050250761-A1 | such as -Piperidin-1-yl-but-2-enoic acid [4(3-chloro-4-fluoro-phenylamino)-7-methoxy-quinazolin-6-yl]-amide, used as tyrosine kinase inhibitors, for the prevention of proliferative diseases, including cancer, atherosclerosis, restenosis, endometriosis and psoriasis | PFIZER INC | 2005-11-10 | — | — | US | claimed |
| US-12612414-B2 | Nitrile SUMO inhibitors and uses thereof | CIT THERAPEUTICS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| EP-3858833-B9 | AMINONORBORNANE DERIVATIVE AND MANUFACTURE METHOD THEREOF AND USE THEREOF | TRANSTHERA SCIENCES NANJING INC (CN) | 2026-03-11 | — | — | EP | disclosed |
| EP-4695256-A2 | ERBB2 INHIBITORS | Cogent Biosciences, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-3858833-B1 | AMINONORBORNANE DERIVATIVE AND MANUFACTURE METHOD THEREOF AND USE THEREOF | TRANSTHERA SCIENCES NANJING INC (CN) | 2025-10-22 | — | — | EP | disclosed |
| US-12291534-B2 | Aminonorbornane derivative and manufacture method therefor and use thereof | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2025-05-06 | — | — | US | disclosed |
| US-20250129078-A1 | ERBB2 INHIBITORS | COGENT BIOSCIENCES, INC. | 2025-04-24 | — | — | US | disclosed |
| EP-4519265-A1 | IRREVERSIBLE MUTEGFR INHIBITORS | Bayer Aktiengesellschaft (DE) | 2025-03-12 | — | — | EP | disclosed |
| US-7772243-B2 | 4-phenylamino-quinazolin-6-yl-amides | WARNER-LAMBERT COMPANY LLC (US) | 2010-08-10 | — | — | US | disclosed |
| US-20100190977-A1 | 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES | PFIZER INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100113520-A1 | KINASE KNOCKDOWN VIA ELECTROPHILICALLY ENHANCED INHIBITORS | PRINCIPIA BIOPHARMA, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113520-A1 | KINASE KNOCKDOWN VIA ELECTROPHILICALLY ENHANCED INHIBITORS | PRINCIPIA BIOPHARMA, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| EP-1746999-A1 | 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES | Warner-Lambert Company LLC (US) | 2007-01-31 | — | — | EP | disclosed |
| WO-2005107758-A1 | 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES | WARNER-LAMBERT COMPANY LLC (US) | 2005-11-17 | — | — | WO | disclosed |
| US-20050250761-A1 | such as -Piperidin-1-yl-but-2-enoic acid [4(3-chloro-4-fluoro-phenylamino)-7-methoxy-quinazolin-6-yl]-amide, used as tyrosine kinase inhibitors, for the prevention of proliferative diseases, including cancer, atherosclerosis, restenosis, endometriosis and psoriasis | PFIZER INC | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12291534-B2 | Aminonorbornane derivative and manufacture method therefor and use thereof | BTK, LCK, SYK | BLM 2148/4885TSHR 3351/4885GABRR1 1073/4885 |
| US-20100190977-A1 | 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES | HRH4, HRH3, HRH2 | BLM 2730/4885TSHR 1704/4885GABRR1 3164/4885 |
| US-12612414-B2 | Nitrile SUMO inhibitors and uses thereof | SUMO1, SUMO3, PSMB6 | BLM 2563/4885TSHR 4265/4885GABRR1 2738/4885 |
| US-20050250761-A1 | such as -Piperidin-1-yl-but-2-enoic acid [4(3-chloro-4-fluoro-phenylamino)-7-methoxy-quinazolin-6-yl]-amide, used as tyrosine kinase inhibitors, for the prevention of proliferative diseases, including cancer, atherosclerosis, restenosis, endometriosis and psoriasis | JAK1, JAK2, EDNRA | BLM 4315/4885TSHR 2676/4885GABRR1 2321/4885 |
| US-20100113520-A1 | KINASE KNOCKDOWN VIA ELECTROPHILICALLY ENHANCED INHIBITORS | MAP3K20, MAP3K6, MAP3K19 | BLM 2706/4885TSHR 3760/4885GABRR1 3050/4885 |
| US-20250129078-A1 | ERBB2 INHIBITORS | ERBB2, ERBB3, EGFR | BLM 4400/4885TSHR 277/4885GABRR1 2373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.